Trial Profile
Efficacy of Natalizumab and Fingolimod in patients with relapsing-remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Nov 2017
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary) ; Fingolimod
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 21 Nov 2017 New trial record
- 28 Oct 2017 Results presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis